Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective Sleep Measures

MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- According to study results presented today at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies (APSS), VEC-162, a balanced melatonin (MT1/MT2) receptor agonist being developed by Vanda Pharmaceuticals Inc. , demonstrated improvements in objective and subjective measures of sleep onset and maintenance in a Phase III trial of transient insomnia.

VEC-162 was assessed in a randomized, double-blind, placebo-controlled, multi-center clinical trial that enrolled 412 adults in a sleep laboratory setting using a phase-advance, first-night assessment model of transient insomnia. The trial examined VEC-162 dosed 30 minutes before bedtime at 20, 50 and 100 mg versus placebo.

"Study patients reported they were falling asleep faster and staying asleep longer," said Tom Roth, Ph.D., Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, presenter at today's APSS session. "These subjective measures support data collected in the sleep lab and provide an important dimension for assessing the efficacy of VEC-162."

VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo (p<0.001) in the primary endpoint of the trial, Latency to Persistent Sleep (LPS), a measure of sleep onset. VEC-162 also produced statistically significant improvements relative to placebo in Latency to Non-Awake (LNA), another measure of sleep onset, Wake After Sleep Onset (WASO), a measure of sleep maintenance, and Total Sleep Time (TST). VEC-162 was also demonstrated to be safe and well tolerated.

VEC-162 also demonstrated improvements relative to placebo on subjective sleep measures. For LPS, all VEC-162 doses showed a trend toward improvement and 50 mg (p<0.001) and 100 mg (p=0.018) achieved statistical
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The Deutsche ... Boston, MA on May 29, 2013 ... ) The public may access Mr. Lindop,s ... About Haemonetics Haemonetics (NYSE: HAE ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... medical technology company, today scheduled a conference call to ... fiscal year 2013, ended April 30, 2013. The call ... 30, 2013. The Company will report financial results for ... markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Dec. 22, 2010 SCOLR Pharma, Inc., a Delaware corporation ... it notified the NYSE Amex Exchange (the "Exchange") of its ... Exchange Commission (the "Commission") to effect the voluntary withdrawal of ... to file the Form 25 with the Commission on or ...
... WPI ) today announced the U.S. Food and ... – the first and only low dose oral contraceptive to ... chewable form, with four 75 mg ferrous fumarate (iron) placebo ... proven effective in lowering the risk of pregnancy. ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 2SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 3SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 4Watson Announces Novel Oral Contraceptive Approval 2Watson Announces Novel Oral Contraceptive Approval 3Watson Announces Novel Oral Contraceptive Approval 4
(Date:5/25/2013)... On May 25, Voices Against Brain Cancer, ... comments on a new study by the Max Planck ... plasma into brain cancer treatment may help when dealing ... Science Daily article, physicists from the Max Planck ... the “synergistic effect of cold atmospheric plasma -- a ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 For ... than finals week. Increasingly, they are turning to ... awake and study. For more on this, go ... drug treatment facility, warns that students who pick ... are at risk for developing a physical and ...
(Date:5/25/2013)... Richmond, Virginia (PRWEB) May 25, 2013 ... bracelet that relieves pain in seconds for arthritis, tendinitis ... innovator in alternative pain relief products announced a ... seconds. The magnetic bracelet for pain relief is demonstrated ... for pain uses 5400 Gauss magnets and has customers ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... to relieve stress, a common cause of heart ... ... us think,of love and Valentine,s Day. This February, which also is National Heart,Awareness ... your heart. A healthy heart can be attained in a variety,of ways that ...
... PORTLAND, Ore. An Oregon Health & Science University Cancer ... the ability to predict if a mans prostate cancer is ... In order to make this discovery, researchers examined prostate cancer ... cancer patients. The researchers found that men whose tumors showed ...
... course of the presidential nomination campaign, some candidates health ... the phrase socialized medicine has been used to attack ... poll by the Harvard Opinion Research Program at the ... finds that Americans are split on whether a socialized ...
... National Board, KNOXVILLE, Tenn., Feb. 14 ... of Stacy Goldsholl, MD, as an,officer of its ... Medicine, is serving her second consecutive term as ... the premier medical society that,represents hospitalists. Hospital medicine ...
... (Nasdaq: DATA ), a technology company focused ... today reported that it will be,presenting at the ... at the Ritz Carlton in Laguna Niguel, California, ... on Wednesday afternoon,February 20th at 2:30 P.M., Pacific ...
... researchers from Europe and North America were given important ... national boundaries at a two-day training course in Croydon, ... Foundation as part of its Pan-European Clinical Trials (ECT) ... trials with a specific focus on the Euramos trial ...
Cached Medicine News:Health News:Healthy Heart, Healthy Home 2Health News:OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Stacy Goldsholl, MD, Re-elected to Board of Society of Hospital Medicine 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 3Health News:ESF's EMRC strengthens training course on clinical trials management 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: